Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC).
Christopher N. Graham
Research Funding - RTI Health Solutions
Hediyyih N. Knox
Research Funding - RTI Health Solutions
Katherine B. Winfree
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Lisa M. Hess
Employment or Leadership Position - Lilly
Jingyi Liu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Waldo Feliu Ortuzar
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ralph Zinner
Research Funding - Lilly